



Aviragen Therapeutics, Inc.  
Investor Relations Department  
2500 Northwinds Parkway  
Suite 100  
Alpharetta, GA 30009  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AVIR**

Last Trade:	0.67
Trade Time:	4:00 PM ET Jan 19, 2018
Change:	0.00 (0.000%)
Day Range	0.66 - 0.72
52-Week Range	0.43 - 1.43
Volume	222,531

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: varendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplatovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papill... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

- Jan 11, 2018*  
[Aviragen Board Of Directors Unanimously Recommends That Stockholders Vote FOR The Proposed Merger With Vaxart](#)
- Nov 29, 2017*  
[Aviragen Therapeutics Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of Teslexivir \(BTA074\) for the Treatment of Condyloma](#)
- Nov 2, 2017*  
[Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results](#)
- Oct 30, 2017*  
[Aviragen Therapeutics and Vaxart Enter into Merger Agreement](#)
- Aug 31, 2017*  
[Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results](#)

## Upcoming Events [\[ View all \]](#)

- Feb 6, 2018*  
[Aviragen Special Meeting Proxy Material](#)
- Nov 7, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)
- Feb 6, 2017*  
[Quarterly Report \(10-Q\)](#)
- Sep 1, 2017*  
[Annual Report \(10-K\)](#)
- Sep 27, 2016*  
[Proxy Statement \(DEF 14A\)](#)
- First Quarter Financial Results*